establishment labs holdings - ESTA
ESTA
Close Chg Chg %
30.18 1.27 4.21%
Pre-Market
31.45
+1.27 (4.21%)
Volume: 558.40K
Last Updated:
Apr 17, 2025, 4:00 PM EDT
Company Overview: establishment labs holdings - ESTA
ESTA Key Data
| Open $30.20 | Day Range 30.09 - 31.91 |
| 52 Week Range 26.56 - 60.12 | Market Cap $870.57M |
| Shares Outstanding 28.85M | Public Float 25.88M |
| Beta 0.78 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.98 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 640.29K |
ESTA Performance
| 1 Week | 3.66% | ||
| 1 Month | -20.72% | ||
| 3 Months | -9.00% | ||
| 1 Year | -33.62% | ||
| 5 Years | 98.80% |
ESTA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About establishment labs holdings - ESTA
Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.
ESTA At a Glance
Establishment Labs Holdings, Inc.
Building B15 and 25
Coyol, Alajuela
| Phone | 506-2434-2400 | Revenue | 166.03M | |
| Industry | Medical Specialties | Net Income | -84,596,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 0.529% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,018 | |
| View SEC Filings |
ESTA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.815 |
| Price to Book Ratio | 24.978 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -33.774 |
| Enterprise Value to Sales | 8.627 |
| Total Debt to Enterprise Value | 0.157 |
ESTA Efficiency
| Revenue/Employee | 163,089.391 |
| Income Per Employee | -83,100.196 |
| Receivables Turnover | 2.554 |
| Total Asset Turnover | 0.54 |
ESTA Liquidity
| Current Ratio | 3.56 |
| Quick Ratio | 2.391 |
| Cash Ratio | 1.323 |
ESTA Profitability
| Gross Margin | 65.969 |
| Operating Margin | -30.108 |
| Pretax Margin | -50.973 |
| Net Margin | -50.954 |
| Return on Assets | -27.49 |
| Return on Equity | -236.665 |
| Return on Total Capital | -30.388 |
| Return on Invested Capital | -34.762 |
ESTA Capital Structure
| Total Debt to Total Equity | 424.322 |
| Total Debt to Total Capital | 80.928 |
| Total Debt to Total Assets | 64.958 |
| Long-Term Debt to Equity | 421.471 |
| Long-Term Debt to Total Capital | 80.384 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Establishment Labs Holdings - ESTA
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 126.68M | 161.70M | 165.15M | 166.03M | |
Sales Growth
| +49.61% | +27.64% | +2.13% | +0.53% | |
Cost of Goods Sold (COGS) incl D&A
| 41.28M | 55.11M | 58.17M | 56.50M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.11M | 4.17M | 4.88M | 7.58M | |
Depreciation
| 2.91M | 2.97M | 3.68M | 5.48M | |
Amortization of Intangibles
| 1.20M | 1.20M | 1.20M | 2.10M | |
COGS Growth
| +28.30% | +33.50% | +5.57% | -2.88% | |
Gross Income
| 85.40M | 106.60M | 106.98M | 109.53M | |
Gross Income Growth
| +62.67% | +24.81% | +0.36% | +2.38% | |
Gross Profit Margin
| +67.42% | +65.92% | +64.78% | +65.97% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 110.54M | 146.25M | 172.00M | 159.51M | |
Research & Development
| 18.32M | 20.27M | 26.43M | 19.71M | |
Other SG&A
| 92.23M | 125.98M | 145.57M | 139.81M | |
SGA Growth
| +37.46% | +32.30% | +17.61% | -7.26% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | (737.00K) | 18.32M | - |
EBIT after Unusual Expense
| (24.40M) | (57.97M) | (65.03M) | (49.99M) | |
Non Operating Income/Expense
| (6.25M) | (3.09M) | 1.84M | (13.81M) | |
Non-Operating Interest Income
| 23.00K | 87.00K | 1.02M | 1.48M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 9.06M | 11.76M | 15.39M | 20.83M | |
Interest Expense Growth
| -3.32% | +29.77% | +30.89% | +35.31% | |
Gross Interest Expense
| 9.06M | 11.76M | 15.39M | 20.83M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (39.71M) | (72.82M) | (78.58M) | (84.63M) | |
Pretax Income Growth
| -4.46% | -83.38% | -7.91% | -7.69% | |
Pretax Margin
| -31.35% | -45.04% | -47.58% | -50.97% | |
Income Tax
| 1.43M | 2.39M | (81.00K) | (32.00K) | |
Income Tax - Current - Domestic
| 289.00K | 114.00K | 297.00K | 183.00K | |
Income Tax - Current - Foreign
| 1.13M | 2.19M | 3.33M | 1.96M | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| 7.00K | 86.00K | (3.71M) | (2.18M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (41.14M) | (75.21M) | (78.50M) | (84.60M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (41.14M) | (75.21M) | (78.50M) | (84.60M) | |
Net Income Growth
| -7.92% | -82.82% | -4.38% | -7.76% | |
Net Margin Growth
| -32.47% | -46.51% | -47.53% | -50.95% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (41.14M) | (75.21M) | (78.50M) | (84.60M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (41.14M) | (75.21M) | (78.50M) | (84.60M) | |
EPS (Basic)
| -1.7161 | -3.0751 | -3.0665 | -3.0039 | |
EPS (Basic) Growth
| -4.96% | -79.19% | +0.28% | +2.04% | |
Basic Shares Outstanding
| 23.97M | 24.46M | 25.60M | 28.16M | |
EPS (Diluted)
| -1.7161 | -3.0751 | -3.0665 | -3.0039 | |
EPS (Diluted) Growth
| -4.96% | -79.19% | +0.28% | +2.04% | |
Diluted Shares Outstanding
| 23.97M | 24.46M | 25.60M | 28.16M | |
EBITDA
| (21.03M) | (35.49M) | (60.14M) | (42.41M) | |
EBITDA Growth
| +13.27% | -68.72% | -69.47% | +29.48% | |
EBITDA Margin
| -16.60% | -21.95% | -36.42% | -25.54% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 55.00 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.522 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -2.077 | |
| Last Quarter’s Earnings | -0.805 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.00 | Next Fiscal Year Estimate | -1.06 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 8 |
| Mean Estimate | -0.52 | -0.49 | -2.08 | -1.06 |
| High Estimates | -0.39 | -0.33 | -1.77 | -0.46 |
| Low Estimate | -0.60 | -0.59 | -2.34 | -1.67 |
| Coefficient of Variance | -11.71 | -17.21 | -9.71 | -35.91 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Buy |
SEC Filings for Establishment Labs Holdings - ESTA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Establishment Labs Holdings - ESTA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 7, 2025 | Rajbir S. Denhoy Chief Financial Officer | 23,348 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 7, 2025 | Rajbir S. Denhoy Chief Financial Officer | 19,716 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 7, 2025 | S. Ross Mansbach | 15,238 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 7, 2025 | S. Ross Mansbach | 13,998 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 7, 2025 | Peter Caldini Int Chief Executive Officer | 25,539 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 7, 2025 | Peter Caldini Int Chief Executive Officer | 30,333 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | Edward J. Schutter Director | 309,364 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $40.81 per share | 12,625,144.84 |
| Apr 2, 2025 | Nicholas S. Lewin Director | 1,071,925 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $40.81 per share | 43,745,259.25 |
| Apr 2, 2025 | Leslie G. Gillin Director | 11,297 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $40.81 per share | 461,030.57 |
| Apr 2, 2025 | Bryan Slotkin Director | 25,559 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $40.81 per share | 1,043,062.79 |
| Apr 2, 2025 | Ann Custin Director | 16,661 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $40.81 per share | 679,935.41 |
| Mar 21, 2025 | Filippo Caldini Int Chief Executive Officer | 8,308 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $34.82 per share | 289,284.56 |
| Jul 12, 2024 | Juan José Chacón-Quirós Chief Executive Officer; Director | 210,735 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.04 per share | 9,491,504.40 |
| Jul 11, 2024 | Juan José Chacón-Quirós Chief Executive Officer; Director | 214,376 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45 per share | 9,646,920.00 |
| Jul 3, 2024 | Dennis E. Condon Director | 8,769 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $45.44 per share | 398,463.36 |